JP Morgan Chase
ABOS icon

JP Morgan Chase’s Acumen Pharmaceuticals ABOS Stock Holding History

JP Morgan Chase’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.8K Buy
20,161
+18,717
+1,296% +$46.2K ﹤0.01% 6378
2026
Q1 		$3.16K Sell
1,444
-965
-40% -$2.46K ﹤0.01% 6946
2025
Q4 		$4.22K Sell
2,409
-623
-21% -$1.24K ﹤0.01% 6833
2025
Q3 		$5.31K Sell
3,032
-13,643
-82% -$18.9K ﹤0.01% 6766
2025
Q2 		$29.2K Sell
16,675
-815,592
-98% -$877K ﹤0.01% 6084
2025
Q1 		$1.46M Sell
832,267
-105,641
-11% -$151K ﹤0.01% 4091
2024
Q4 		$1.61M Buy
937,908
+874,842
+1,387% +$2.11M ﹤0.01% 4307
2024
Q3 		$156K Buy
63,066
+45,189
+253% +$123K ﹤0.01% 5516
2024
Q2 		$60.1K Sell
17,877
-54,013
-75% -$172K ﹤0.01% 5777
2024
Q1 		$291K Buy
71,890
+37,945
+112% +$143K ﹤0.01% 5116
2023
Q4 		$130K Buy
33,945
+22,920
+208% +$68K ﹤0.01% 5612
2023
Q3 		$46K Buy
11,025
+9,750
+765% +$60.2K ﹤0.01% 5836
2023
Q2 		$6.13K Buy
1,275
+38
+3% +$182 ﹤0.01% 6137
2023
Q1 		$5K Buy
1,237
+108
+10% +$564 ﹤0.01% 6234
2022
Q4 		$6K Sell
1,129
-1,298
-53% -$8.72K ﹤0.01% 6113
2022
Q3 		$24K Buy
2,427
+805
+50% +$4.62K ﹤0.01% 5752
2022
Q2 		$8K Sell
1,622
-16,427
-91% -$61.7K ﹤0.01% 6067
2022
Q1 		$71K Buy
18,049
+10,809
+149% +$58.8K ﹤0.01% 5648
2021
Q4 		$49K Buy
7,240
+3,568
+97% +$39.2K ﹤0.01% 5953
2021
Q3 		$55K Buy
+3,672
New +$61.1K ﹤0.01% 5807

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

JP Morgan Chase's ABOS Position: Q2 2026 in Review

JP Morgan Chase increased its Acumen Pharmaceuticals (ABOS) stake by 1,296% in Q2 2026, buying an estimated $46.2K and bringing the position to 20,161 shares worth $55.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6378.

JP Morgan Chase first reported a position in ABOS in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.61M in Q4 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • JP Morgan Chase held 20,161 shares of Acumen Pharmaceuticals worth $55.8K as of Q2 2026.
  • JP Morgan Chase bought 18,717 Acumen Pharmaceuticals shares in Q2 2026, an estimated $46.2K.
  • Acumen Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6378 holding.
  • JP Morgan Chase first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Acumen Pharmaceuticals position peaked at $1.61M in Q4 2024.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.